Viability and recovery of peripheral blood mononuclear cells cryopreserved for up to 12 years in a multicenter study.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Viability and recovery of peripheral blood mononuclear cells cryopreserved for up to 12 years in a multicenter study.

Clin Diagn Lab Immunol. 1999 Jan;6(1):14-9. Unique Identifier : AIDSLINE MED/99091873
Kleeberger CA; Lyles RH; Margolick JB; Rinaldo CR; Phair JP; Giorgi JV; Department of Epidemiology, Johns Hopkins School of Public; Health, Baltimore, Maryland 21205, USA. ckleeber@jhsph.edu

Abstract: The Multicenter AIDS Cohort Study (MACS), an ongoing prospective study of the natural history of human immunodeficiency virus (HIV), has stored biologic specimens, including peripheral blood mononuclear cells (PBMC), from 5,622 participants for up to 12 years. The purpose of the present analysis was to evaluate the quality of the PBMC in the MACS repository in order to test the validity and feasibility of nested retrospective studies and to guide the planning of future repositories. PBMC were collected from MACS participants at four centers at 6-month intervals from 1984 to 1995, cryopreserved, and transported to a central repository for storage. A total of 596 of these specimens were subsequently tested for viability and used to evaluate cell function, to conduct immunophenotype analysis, or to isolate HIV. Simple linear regression models were applied to evaluate trends in recovery and viability over time and by center. Results indicated that from a nominal 10(7) cells cryopreserved per vial at all four centers, the median number of viable cells recovered was at least 5 x 10(6) (50% of the number stored) and the median viability was at least 90%. Results suggested that cryopreserved cells can be stored for at least 12 years with no general tendency toward cell loss over time. Furthermore, there were no statistically significant changes in the percent cell viability according to the length of time frozen, regardless of HIV serostatus or the level of CD4(+) lymphocytes. Storing 10(7) PBMC per vial yields sufficient viable cells for phenotypic and/or functional analysis. Results from the MACS provide the basis for the planning of future repositories for use by investigators with similar research goals.

Keywords: JOURNAL ARTICLE MULTICENTER STUDY *Blood Preservation Cell Survival Cohort Studies *Cryopreservation CD4 Lymphocyte Count Human HIV Infections/BLOOD/IMMUNOLOGY/VIROLOGY *Leukocytes, Mononuclear/CYTOLOGY Prospective Studies Support, U.S. Gov't, P.H.S. Time Factors
990530
A9950937

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .